Autologous hematopoietic stem-cell transplantation in neurological disorders: current approach and future directions

References

• Fassas A, Anagnostopoulos A, Kazis A, et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant. 1997;20:631–638.
   PubMed Web of Science ®Google Scholar
• Burt R, Traynor A, Cohen B, et al. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. Bone Marrow Transplant. 1998;21:537–541.
   PubMed Web of Science ®Google Scholar
• Cooley HM, Snowden JA, Grigg AP, et al. Outcome of rheumatoid arthritis and psoriasis following autologous stem cell transplantation for hematologic malignancy. Arthritis Rheum. 1997;40:1712–1715.
   PubMed Web of Science ®Google Scholar
• Marmont A, van Lint M, Gualandi F, et al. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration. Lupus. 1997;6:545–548.
   PubMed Web of Science ®Google Scholar
• Binks M, Passweg JR, Furst D, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis. 2001;60:577–584.
   PubMed Web of Science ®Google Scholar
• Massey JC, Sutton IJ, Ma DDF, et al. Regenerating immunotolerance in multiple sclerosis with autologous hematopoietic stem cell transplant. Front Immunol. 2018;9:410.
   PubMed Web of Science ®Google Scholar
• Malmegrim KCR, Lima-Júnior JR, Arruda LCM, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: from mechanistic insights to biomarkers. Front Immunol. 2018. doi:10.3389/fimmu.2018.02602.
   Google Scholar
• Muraro PA, Douek DC, Packer A, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med. 2005;201:805–816.
   PubMed Web of Science ®Google Scholar
• Amoriello R, Greiff V, Aldinucci A, et al. The TCR repertoire reconstitution in multiple sclerosis: comparing one-shot and continuous immunosuppressive therapies. Front Immunol. 2020;11:599.
   PubMed Web of Science ®Google Scholar
• Darlington PJ, Touil T, Doucet J-S, et al. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol. 2013;73:341–354.
   PubMed Web of Science ®Google Scholar
• Arruda LCM, Lima-Júnior JR, Clave E, et al. Homeostatic proliferation leads to telomere attrition and increased PD-1 expression after autologous hematopoietic SCT for systemic sclerosis. Bone Marrow Transplant. 2018;53:1319–1327.
   PubMed Web of Science ®Google Scholar
• Burman J, Fransson M, Tötterman TH, et al. T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis. Immunology. 2013;140:211–219.
   PubMed Web of Science ®Google Scholar
• Harris KM, Lim N, Lindau P, et al. Extensive intrathecal T cell renewal following hematopoietic transplantation for multiple sclerosis. JCI Insight. 2020;5(2):e127655.
   Web of Science ®Google Scholar
• Pasquini MC, Voltarelli J, Atkins HL, et al. Transplantation for autoimmune diseases in north and south america: a report of the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2012;18:1471–1478.
   PubMed Web of Science ®Google Scholar
• Snowden JA, Badoglio M, Labopin M, et al. Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Adv. 2017;1:2742–2755.
   PubMed Web of Science ®Google Scholar
• Das J, Sharrack B, Snowden JA. Autologous haematopoietic stem cell transplantation in multiple sclerosis: a review of current literature and future directions for transplant haematologists and oncologists. Curr Hematol Malig Rep. 2019;14(2):127–135.
   Web of Science ®Google Scholar
• Muraro PA, Martin R, Mancardi GL, et al. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol. 2017;13:391–405.
   PubMed Web of Science ®Google Scholar
• Blank N, Lisenko K, Pavel P, et al. Low-dose cyclophosphamide effectively mobilizes peripheral blood stem cells in patients with autoimmune disease. Eur J Haematol. 2016;97:78–82.
   PubMed Web of Science ®Google Scholar
• Snowden JA, Saccardi R, Allez M, et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2012;47:770–790.
   PubMed Web of Science ®Google Scholar
• Openshaw H, Stuve O, Antel JP, et al. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology. 2000;54:2147–2150.
   PubMed Web of Science ®Google Scholar
• Nash RA, Hutton GJ, Racke MK, et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology. 2017;88:842–852.
   PubMed Web of Science ®Google Scholar
• Shevchenko JL, Kuznetsov AN, Ionova TI, et al. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician’s and patient’s perspectives. Ann Hematol. 2015;94:1149–1157.
   PubMed Web of Science ®Google Scholar
• Yvonne Loh S, Ratnagopal P, Patrick Tan H, et al. Successful autologous hematopoietic stem cell transplantations for severe multiple sclerosis with fludarabine and cyclophosphamide conditioning. Int J Hematol. 2006;83:368–369.
   PubMed Web of Science ®Google Scholar
• Rabusin M, Andolina M, Maximova N, et al. Immunoablation followed by autologous hematopoietic stem cell infusion for the treatment of severe autoimmune disease. Haematologica. 2000;85:81–85.
   PubMedGoogle Scholar
• Atkins HL, Bowman M, Allan D, et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet. 2016;388:576–585.
   PubMed Web of Science ®Google Scholar
• Burman J, Iacobaeus E, Svenningsson A, et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. J Neurol Neurosurg Psychiatry. 2014;85:1116–1121.
   PubMed Web of Science ®Google Scholar
• Burt RK, Loh Y, Cohen B, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol. 2009;8:244–253.
   PubMed Web of Science ®Google Scholar
• Burt RK, Balabanov R, Han X, et al. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. JAMA. 2015;313:275–284.
   PubMed Web of Science ®Google Scholar
• Burt RK, Balabanov R, Han X, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica. Neurology. 2019;93:E1732–E1741.
   PubMed Web of Science ®Google Scholar
• Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple Sclerosis: mechanisms and Immunotherapy. Neuron. 2018;97:742–768.
   PubMed Web of Science ®Google Scholar
• Pugliatti M, Rosati G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006;13:700–722.
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989;112(Pt 1):133–146. .
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Turner B, Gnanapavan S, et al. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord. 2015;4:329–333.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Disability rating scales in multiple sclerosis. Ann N Y Acad Sci. 1984;436:347–360.
   PubMed Web of Science ®Google Scholar
• Havrdova E, Arnold DL, Cohen JA, et al. Alemtuzumab CARE-MS I 5-year follow-up. Neurology. 2017;89:1107–1116.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Cohen JA, Fox EJ, et al. Alemtuzumab CARE-MS II 5-year follow-up. Neurology. 2017;89:1117–1126.
   PubMed Web of Science ®Google Scholar
• Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8:254–260.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221–234.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Cook S, Rammohan K, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 2011;10:329–337.
   PubMed Web of Science ®Google Scholar
• Krasulová E, Trněný M, Kozák T, et al. High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Mult Scler J. 2010;16:685–693.
   PubMed Web of Science ®Google Scholar
• Mancardi G, Sormani M, Di Gioia M, et al. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Mult Scler J. 2012;18:835–842.
   PubMed Web of Science ®Google Scholar
• Chen B, Zhou M, Ouyang J, et al. Long-term efficacy of autologous haematopoietic stem cell transplantation in multiple sclerosis at a single institution in China. Neurol Sci. 2012;33:881–886.
   PubMed Web of Science ®Google Scholar
• Casanova B, Jarque I, Gascón F, et al. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis. Neurol Sci. 2017;38:1213–1221.
   PubMed Web of Science ®Google Scholar
• Hamerschlak N, Rodrigues M, Moraes DA, et al. Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG. Bone Marrow Transplant. 2010;45:239–248.
   PubMed Web of Science ®Google Scholar
• Shevchenko JL, Kuznetsov AN, Ionova TI, et al. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis. Exp Hematol. 2012;40:892–898.
   PubMed Web of Science ®Google Scholar
• Burt RK, Balabanov R, Burman J, et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis. JAMA. 2019;321:165.
   PubMed Web of Science ®Google Scholar
• NIHR Funding and Awards Search Website [Internet]. [cited 2020 Jun 12]. Available from: https://www.fundingawards.nihr.ac.uk/award/16/126/26.
   Google Scholar
• Muraro PA, Pasquini M, Atkins HL, et al. Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol. 2017;74:459.
   PubMed Web of Science ®Google Scholar
• Mariottini A, Filippini S, Innocenti C, et al. Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis. Mult Scler J 2020 135245852090239 doi:10.1177/1352458520902392
   Web of Science ®Google Scholar
• Bowen JD, Kraft GH, Wundes A, et al. Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results. Bone Marrow Transplant. 2012;47:946–951.
   PubMed Web of Science ®Google Scholar
• Menon S, Shirani A, Zhao Y, et al. Characterising aggressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013;84:1192–1198.
   PubMed Web of Science ®Google Scholar
• Menon S, Zhu F, Shirani A, et al. Disability progression in aggressive multiple sclerosis. Mult Scler J. 2017;23:456–463.
   PubMed Web of Science ®Google Scholar
• Gholipour T, Healy B, Baruch NF, et al. Demographic and clinical characteristics of malignant multiple sclerosis. Neurology. 2011;76:1996–2001.
   PubMed Web of Science ®Google Scholar
• Hampshire-Araújo F, Bergmann A, Alvarenga RMP, et al. Malignant multiple sclerosis: clinical and demographic prognostic factors. Arq Neuropsiquiatr. 2017;75:139–141.
   PubMed Web of Science ®Google Scholar
• Kaunzner UW, Kumar G, Askin G, et al. A study of patients with aggressive multiple sclerosis at disease onset. Neuropsychiatr Dis Treat. 2016;12:1907–1912.
   PubMed Web of Science ®Google Scholar
• Rush CA, MacLean HJ, Freedman MS. Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol. 2015;11:379–389.
   PubMed Web of Science ®Google Scholar
• Freedman MS. Multiple sclerosis: does aggressive MS warrant aggressive treatment? Nat Rev Neurol. 2014;10:368–370.
   PubMedGoogle Scholar
• Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129:606–616.
   PubMed Web of Science ®Google Scholar
• Sharrack B, Saccardi R, Alexander T, et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplant. 2020;55(2):283-308.
   Web of Science ®Google Scholar
• Snowden JA, Sharrack B, Akil M, et al. Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases – a guide for the generalist. Clin Med (Northfield Il). 2018;18:329–334.
   PubMed Web of Science ®Google Scholar
• Jindahra P, Plant G. Update on neuromyelitis optica: natural history and management. Eye Brain. 2012;4:27.
   PubMedGoogle Scholar
• Wingerchuk DM, Pittock SJ, Lucchinetti CF, et al. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology. 2007;68:603–605.
   PubMed Web of Science ®Google Scholar
• Asgari N, Lillevang ST, Skejoe HPB, et al. A population-based study of neuromyelitis optica in Caucasians. Neurology. 2011;76:1589–1595.
   PubMed Web of Science ®Google Scholar
• Cabrera-Gómez J, Bonnan M, González-Quevedo A, et al. Neuromyelitis optica positive antibodies confer a worse course in relapsing-neuromyelitis optica in Cuba and French West Indies. Mult Scler J. 2009;15:828–833.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007;130:1235–1243.
   PubMed Web of Science ®Google Scholar
• Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261:1–16.
   PubMed Web of Science ®Google Scholar
• Jacob A, Panicker J, Lythgoe D, et al. The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. J Neurol. 2013;260:2134–2137.
   PubMed Web of Science ®Google Scholar
• Collongues N, Marignier R, Zéphir H, et al. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology. 2010;74:736–742.
   PubMed Web of Science ®Google Scholar
• Ghezzi A, Bergamaschi R, Martinelli V, et al. Clinical characteristics, course and prognosis of relapsing Devic?s Neuromyelitis Optica. J Neurol. 2004;251:47–52.
   PubMed Web of Science ®Google Scholar
• Nikoo Z, Badihian S, Shaygannejad V, et al. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol. 2017;264:2003–2009.
   PubMed Web of Science ®Google Scholar
• Bedi GS, Brown AD, Delgado SR, et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler J. 2011;17:1225–1230.
   PubMed Web of Science ®Google Scholar
• Kim S-H, Kim W, Li XF, et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011;68:1412.
   PubMedGoogle Scholar
• Zhu W, Zhang Y, Wang Z, et al. Monoclonal antibody-based treatments for neuromyelitis optica spectrum disorders: from bench to bedside. Neurosci Bull. 2020. Springer. doi:10.1007/s12264-020-00525-3
   Web of Science ®Google Scholar
• Peng F, Qiu W, Li J, et al. A preliminary result of treatment of neuromyelitis optica with autologous peripheral hematopoietic stem cell transplantation. Neurologist. 2010;16:375–378.
   PubMed Web of Science ®Google Scholar
• Greco R, Bondanza A, Vago L, et al. Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. Ann Neurol. 2014;75:447–453.
   PubMed Web of Science ®Google Scholar
• Aouad P, Li J, Arthur C, et al. Resolution of aquaporin-4 antibodies in a woman with neuromyelitis optica treated with human autologous stem cell transplant. J Clin Neurosci. 2015;22:1215–1217.
   PubMed Web of Science ®Google Scholar
• Hoay KY, Ratnagopal P. Autologous hematopoietic stem cell transplantation for the treatment of neuromyelitis optica in Singapore. Acta Neurol Taiwan. 2018;27:26–32.
   PubMedGoogle Scholar
• Matiello M, Pittock SJ, Porrata L, et al. Failure of autologous hematopoietic stem cell transplantation to prevent relapse of neuromyelitis optica. Arch Neurol. 2011;68:953–955.
   PubMedGoogle Scholar
• Greco R, Bondanza A, Oliveira MC, et al. Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party. Mult Scler J. 2015;21:189–197.
   PubMed Web of Science ®Google Scholar
• MOERSCH FP, Woltman HW. Progressive fluctuating muscular rigidity and spasm stiff-man syndrome. Report of a case and some observations in 13 other cases. Proc Staff Meet Mayo Clin. 1956;31:421–427.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Stiff person syndrome: advances in pathogenesis and therapeutic interventions. Curr Treat Options Neurol. 2009;11:102–110.
   PubMed Web of Science ®Google Scholar
• Sarva H, Deik A, Ullah A, et al. Clinical spectrum of stiff person syndrome: a review of recent reports. Tremor Other Hyperkinet Mov (N Y). 2016;6:340.
   PubMed Web of Science ®Google Scholar
• Khasani S, Becker K, Meinck HM. Hyperekplexia and stiff-man syndrome: abnormal brainstem reflexes suggest a physiological relationship. J Neurol Neurosurg Psychiatry. 2004;75:1265–1269.
   PubMed Web of Science ®Google Scholar
• Dekker MCJ, Urasa SJ, Kinabo G, et al. A report of stiff person syndrome in Tanzania with first epidemiological figures for Sub-Saharan Africa. Neuroepidemiology. 2015;45:109–110.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Fujii M, Li M, et al. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med. 2001;345:1870–1876.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Rakocevic G, Dambrosia JM, et al. A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome. Ann Neurol. 2017;82:271–277.
   PubMed Web of Science ®Google Scholar
• Sanders S, Bredeson C, Pringle CE, et al. Autologous stem cell transplantation for stiff person syndrome: two cases from the Ottawa blood and marrow transplant program. JAMA Neurol. 2014;71:1296–1299.
   PubMed Web of Science ®Google Scholar
• Georges GE, Bowen JD, Pearlman M, et al. Autologous hematopoietic stem cell transplantation may be highly effective treatment for severe stiff person syndrome. Biol Blood Marrow Transplant. 2018;24:S120.
   Google Scholar
• Georges G, McSweeney P, Bowen J, et al. Autologous hematopoietic stem cell transplantation may be highly effective treatment for severe, treatment refractory stiff person syndrome. Neurology. 2018;90 (15 supplement):S31.007.
   Web of Science ®Google Scholar
• Kass-Iliyya L, Snowden JA, Thorpe A, et al. Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience. J Neurol. 2020. DOI:10.1007/s00415-020-10054-8.
   PubMed Web of Science ®Google Scholar
• Stem cell transplantation for stiff person syndrome (SPS) - full text view - ClinicalTrials.gov [Internet]. [cited 2020 Jul 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT02282514.
   Google Scholar
• Chan V, Soans B, Mathers D. Ultrasound and magnetic resonance imaging features in a patient with eosinophilic fasciitis. Australas Radiol. 2004;48:414–417.
   PubMedGoogle Scholar
• Laughlin RS, Dyck PJ, Melton LJ, et al. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology. 2009;73:39–45.
   PubMed Web of Science ®Google Scholar
• Mygland A, Monstad P. Chronic polyneuropathies in Vest-Agder, Norway. Eur J Neurol. 2001;8:157–165.
   PubMed Web of Science ®Google Scholar
• Chiò A, Cocito D, Bottacchi E, et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry. 2007;78:1349–1353.
   PubMed Web of Science ®Google Scholar
• PA MCOMBE, JD POLLARD, JG M. Chronic inflammatory demyelinating polyradiculoneuropathy. Brain. 1987;110:1617–1630.
   PubMed Web of Science ®Google Scholar
• McLeod JG, Pollard JD, Macaskill P, et al. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol. 1999;46:910–913.
   PubMed Web of Science ®Google Scholar
• Mathey EK, Park SB, Hughes RAC, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry. 2015;86:973–985.
   PubMed Web of Science ®Google Scholar
• Simmons Z, Albers JW, Bromberg MB, et al. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain. 1995;118:359–368.
   PubMed Web of Science ®Google Scholar
• Allen JA, Ney J, Lewis RA. Electrodiagnostic errors contribute to chronic inflammatory demyelinating polyneuropathy misdiagnosis. Muscle Nerve. 2018;57:542–549.
   PubMed Web of Science ®Google Scholar
• Allen JA, Lewis RA. CIDP diagnostic pitfalls and perception of treatment benefit. Neurology. 2015;85:498–504.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, O’Brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982;11:136–141.
   PubMed Web of Science ®Google Scholar
• Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: A double-blind, sham-controlled, cross-over study. Brain. 1996;119:1055–1066.
   PubMed Web of Science ®Google Scholar
• Hahn AF, Bolton CF, Zochodne D, et al. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled, cross-over study. Brain. 1996;119:1067–1077.
   PubMed Web of Science ®Google Scholar
• Kuwabara S, Misawa S, Mori M, et al. Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases. J Neurol Neurosurg Psychiatry. 2006;77:66–70.
   PubMed Web of Science ®Google Scholar
• Vermeulen M, Van Oers MH. Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 2002;72:127–128.
   PubMed Web of Science ®Google Scholar
• Vermeulen M, van Oers MHJ. Relapse of chronic inflammatory demyelinating polyneuropathy 5 years after autologous stem cell transplantation. J Neurol Neurosurg Psychiatry. 2007;78:1154.
   PubMed Web of Science ®Google Scholar
• Mahdi-Rogers M, Kazmi M, Ferner R, et al. Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy. J Peripher Nerv Syst. 2009;14:118–124.
   PubMed Web of Science ®Google Scholar
• Press R, Askmark H, Svenningsson A, et al. Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP. J Neurol Neurosurg Psychiatry. 2014;85:618–624.
   PubMed Web of Science ®Google Scholar
• Barreira A, Marques W, Rezende C, et al. Autologous stem cell transplantation in a patient with a chronic demyelinating neuropathy and persistent conduction block. 2007.
   Google Scholar
• Scheibe F, Alexander T, Prüss H, et al. Devastating humoral CIDP variant remitted by autologous stem cell transplantation. Eur J Neurol. 2016;23:e12–4.
   PubMed Web of Science ®Google Scholar
• Axelson HW, Oberg G, Askmark H. Successful repeated treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP. J Neurol Neurosurg Psychiatry. 2008;79:612–614.
   PubMed Web of Science ®Google Scholar
• Kamat A, Elston T, Tueger S. Autologous peripheral blood progenitor cell transplantation in refractory chronic inflammatory demyelinating polyradiculopathy. Bone Marrow Transplant. 2006;38:S132.
   Google Scholar
• Oyama Y, Sufit R, Loh Y, et al. Nonmyeloablative autologous hematopoietic stem cell transplantation for refractory CIDP. Neurology. 2007;69:1802–1803.
   PubMed Web of Science ®Google Scholar
• Bregante S, Gualandi F, van Lint MT, et al. Sjögren’s syndrome associated chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) treated with autologous and subsequently allogeneic haematopoietic SCT (HSCT). Bone Marrow Transplant. 2013;48:1139–1140.
   PubMed Web of Science ®Google Scholar
• Burt RK, Balabanov R, Tavee J, et al. Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol. 2020;27 (Online a head of print).
   Web of Science ®Google Scholar
• Reményi P, Masszi T, Borbényi Z, et al. CIDP cured by allogeneic hematopoietic stem cell transplantation. Eur J Neurol. 2007;14:e1–2.
   PubMed Web of Science ®Google Scholar
• Brown R, Ginsberg L. POEMS syndrome: clinical update. J Neurol. 2019;266(1):268–277.
   Google Scholar
• Karam C, Klein CJ, Dispenzieri A, et al. Polyneuropathy improvement following autologous stem cell transplantation for POEMS syndrome. Neurology. 2015;84:1981–1987.
   PubMed Web of Science ®Google Scholar
• Cook G, Iacobelli S, van Biezen A, et al. High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation. Haematologica. 2017;102:160–167.
   PubMed Web of Science ®Google Scholar
• Galassi G, Tondelli M, Ariatti A, et al. Long-term disability and prognostic factors in polyneuropathy associated with anti-myelin-associated glycoprotein (MAG) antibodies. Int J Neurosci. 2017;127:439–447.
   PubMed Web of Science ®Google Scholar
• Lawson VH, Arnold WD. Multifocal motor neuropathy: a review of pathogenesis, diagnosis, and treatment. Neuropsychiatr Dis Treat. 2014;10:567–576.
   PubMed Web of Science ®Google Scholar
• Axelson HW, Öberg G, Askmark H. No benefit of treatment with cyclophosphamide and autologous blood stem cell transplantation in multifocal motor neuropathy. Acta Neurol Scand. 2007;117:432–434.
   PubMed Web of Science ®Google Scholar
• Gilhus NE. Myasthenia Gravis. Longo DL, editor. N Engl J Med. 2016;375:2570–2581.
   PubMed Web of Science ®Google Scholar
• Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet. 2001;357:2122–2128.
   PubMed Web of Science ®Google Scholar
• Huang Y-C, Yeh J-H, Chiu H-C, et al. Clinical characteristics of MuSK antibody-positive myasthenia gravis in Taiwan. J Formos Med Assoc. 2008;107:572–575.
   PubMed Web of Science ®Google Scholar
• JM LINDSTROM, ME SEYBOLD, VA LENNON, et al. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology. 1998;51:933.
   PubMed Web of Science ®Google Scholar
• Akaishi T, Suzuki Y, Imai T, et al. Response to treatment of myasthenia gravis according to clinical subtype. BMC Neurol. 2016;16:225.
   PubMed Web of Science ®Google Scholar
• Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry. 1989;52:1121–1127.
   PubMed Web of Science ®Google Scholar
• Heckmann JM, Rawoot A, Bateman K, et al. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol. 2011;11:97.
   PubMed Web of Science ®Google Scholar
• Howard JF, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16:976–986.
   PubMed Web of Science ®Google Scholar
• Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord. 2018;11:1756285617749134.
   Web of Science ®Google Scholar
• Yoshikawa H, Kiuchi T, Saida T, et al. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2011;82:970–977.
   PubMed Web of Science ®Google Scholar
• Suh J, Goldstein JM, Nowak RJ. Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med. 2013;86:255–260.
   PubMedGoogle Scholar
• Baggi F, Andreetta F, Maggi L, et al. Complete stable remission and autoantibody specificity in myasthenia gravis. Neurology. 2013;80:188–195.
   PubMed Web of Science ®Google Scholar
• Burt RK, Statkute L, Gourineni R, et al. Treatment of refractory myasthenia gravis with high dose chemotherapy and autologous hematopoietic stem cell transplantation. Neurology. 2004;62:A497.
   Web of Science ®Google Scholar
• Bryant A, Atkins H, Pringle CE, et al. Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation. JAMA Neurol. 2016;73:652.
   PubMed Web of Science ®Google Scholar
• Håkansson I, Sandstedt A, Lundin F, et al. Successful autologous haematopoietic stem cell transplantation for refractory myasthenia gravis - a case report. Neuromuscul Disord. 2017;27:90–93.
   PubMed Web of Science ®Google Scholar
• Mitsumune S, Manabe Y, Yunoki T, et al. Autologous bone marrow transplantation for polymyositis combined with myasthenia gravis and aplastic anemia: a case report. Case Rep Neurol. 2018;10:108–111.
   PubMed Web of Science ®Google Scholar
• Sossa Melo CL, Peña AM, Salazar LA, et al. Autologous hematopoietic stem cell transplantation in a patient with refractory seropositive myasthenia gravis: A case report. Neuromuscul Disord. 2019;29:142–145.
   PubMed Web of Science ®Google Scholar
• Oliveira MC, Labopin M, Henes J, et al. Erratum: does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients? Bone Marrow Transplant. 2016;51:889.
   PubMedGoogle Scholar
• Alchi B, Jayne D, Labopin M, et al. Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry. Lupus. 2013;22(3):245–253.
   PubMed Web of Science ®Google Scholar
• Chan J, Ban EJ, Chun KH, et al. Transplantation of bone marrow transduced to express self-antigen establishes deletional tolerance and permanently remits autoimmune disease. J Immunol. 2008;181:7571–7580.
   PubMed Web of Science ®Google Scholar
• Xu B, Haviernik P, Wolfraim LA, et al. Bone marrow transplantation combined with gene therapy to induce antigen-specific tolerance and ameliorate EAE. Mol Ther. 2006;13:42–48.
   PubMed Web of Science ®Google Scholar
• Pistoia V, Raffaghello L. Mesenchymal stromal cells and autoimmunity. Int Immunol. 2017;29:49–58.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Tammik C, Rosendahl K, et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003;31:890–896.
   PubMed Web of Science ®Google Scholar
• Connick P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012;11:150–156.
   PubMed Web of Science ®Google Scholar
• Pluchino S, Smith JA, Peruzzotti-Jametti L. Promises and limitations of neural stem cell therapies for progressive multiple sclerosis. Trends Mol Med. 2020;S1471–4914(20):30123–4.
   PubMed Web of Science ®Google Scholar
• Kim H, Walczak P, Kerr C, et al. Immunomodulation by transplanted human embryonic stem cell-derived oligodendroglial progenitors in experimental autoimmune encephalomyelitis. Stem Cells. 2012;30:2820–2829.
   PubMed Web of Science ®Google Scholar
• Jadasz JJ, Lubetzki C, Zalc B, et al. Recent achievements in stem cell-mediated myelin repair. Curr Opin Neurol. 2016;29(3):205–212.
   Web of Science ®Google Scholar
• Zhang B, Yeo RWY, Tan KH, et al. Focus on extracellular vesicles: therapeutic potential of stem cell-derived extracellular vesicles. Int J Mol Sci. 2016;17(2):174.
   Google Scholar
• Sáenz-Cuesta M, Osorio-Querejeta I, Otaegui D. Extracellular Vesicles in Multiple Sclerosis: what are They Telling Us? Front Cell Neurosci. 2014;8:100.
   PubMedGoogle Scholar
• Koniusz S, Andrzejewska A, Muraca M, et al. Extracellular vesicles in physiology, pathology, and therapy of the immune and central nervous system, with focus on extracellular vesicles derived from mesenchymal stem cells as therapeutic tools. Front Cell Neurosci. 2016;10:109.
   PubMed Web of Science ®Google Scholar
• Malmegrim KCR, Lima-Júnior JR, Arruda LCM, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: from mechanistic insights to biomarkers. Front Immunol. 2018;9:2602.
   PubMed Web of Science ®Google Scholar
• Mackenzie IS, Morant SV, Bloomfield GA, et al. Incidence and prevalence of multiple sclerosis in the UK 1990-2010: A descriptive study in the General Practice Research Database. J Neurol Neurosurg Psychiatry. 2014;85:79–84.
   Web of Science ®Google Scholar
• Ma VY, Chan L, Carruthers KJ. Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and back pain. Arch Phys Med Rehabil. 2014;95(5):986–995.
   Google Scholar
• Batcheller L, Baker D. Cost of disease modifying therapies for multiple sclerosis: is front-loading the answer?. J Neurol Sci Elsevier B.V. 2019;404:19–28.
   Google Scholar
• Tappenden P, Saccardi R, Confavreux C, et al. Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis. Bone Marrow Transplant. 2010;45:1014–1021.
   PubMed Web of Science ®Google Scholar
• Burt RK, Tappenden P, Han X, et al. Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America. Mult Scler Relat Disord. 2020;45:102404.
   PubMed Web of Science ®Google Scholar
• Battaglia M, Kobelt G, Ponzio M, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Italy. Mult Scler J. 2017;23:104–116.
   PubMed Web of Science ®Google Scholar
• Brundin L, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Sweden. Mult Scler J. 2017;23:179–191.
   PubMed Web of Science ®Google Scholar
• Péntek M, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Hungary. Mult Scler J. 2017;23:91–103.
   PubMed Web of Science ®Google Scholar
• Flachenecker P, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Germany. Mult Scler J. 2017;23:78–90.
   PubMed Web of Science ®Google Scholar
• Uitdehaag B, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for The Netherlands. Mult Scler J. 2017;23:117–129.
   PubMed Web of Science ®Google Scholar
• Calabrese P, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Switzerland. Mult Scler. 2017;23:192–203.
   PubMed Web of Science ®Google Scholar
• Oreja-Guevara C, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Spain. Mult Scler. 2017;23:166–178.
   PubMed Web of Science ®Google Scholar
• Dubois B, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Belgium. Mult Scler. 2017;23:29–40.
   PubMed Web of Science ®Google Scholar
• Berger T, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Austria. Mult Scler. 2017;23:17–28.
   PubMed Web of Science ®Google Scholar
• Havrdova E, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results of the Czech Republic. Mult Scler J. 2017;23:41–52.
   PubMed Web of Science ®Google Scholar
• Sá MJ, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Portugal. Mult Scler J. 2017;23:143–154.
   PubMed Web of Science ®Google Scholar
• Selmaj K, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Poland. Mult Scler J. 2017;23:130–142.
   PubMed Web of Science ®Google Scholar
• Thompson A, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for the United Kingdom. Mult Scler J. 2017;23:204–216.
   PubMed Web of Science ®Google Scholar
• Lebrun-Frenay C, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for France. Mult Scler. 2017;23:65–77.
   PubMed Web of Science ®Google Scholar
• Rasmussen PV, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Denmark. Mult Scler J. 2017;23:53–64.
   PubMed Web of Science ®Google Scholar
• Boyko A, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Russia. Mult Scler. 2017;23:155–165.
   PubMed Web of Science ®Google Scholar
• Tappenden P, Wang Y, Sharrack B, et al. Evaluating the clinical effectiveness of autologous haematopoietic stem cell transplantation versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison: an exploratory study from the Autoimmune Diseases Working Party (ADWP) of the European Society of Bone and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2020;55(7):1473–1475.
   Web of Science ®Google Scholar